Published in Drug Law Weekly, May 1st, 2007
Total revenues in the first quarter of 2007 were $4.9 million, compared to $12.1 million in the first quarter of 2006. Revenues in the first quarter of 2006 included a $5.0 million milestone under our collaboration with Ortho-McNeil Pharmaceutical, Inc. related to the initiation of a Phase 1 clinical trial of APD668 for the treatment of type 2 diabetes. Arena reported a net loss allocable to common stockholders in the first quarter of 2007 of $32.4 million, or $0.53 per share. This compares with a net loss allocable to common stockholders in the first quarter...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.